NCT03804645 - A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

April 16, 2019

Study Completion Date

April 16, 2019

Conditions

Heart Failure

Interventions

DRUG

Treatment A

Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

DRUG

Treatment B

Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

DRUG

Treatment C

Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.

DRUG

Treatment D

Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow